tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Touyun Biotech Announces Strategic Cooperation Amid Unusual Market Activity

Story Highlights
  • Touyun Biotech operates in biotechnology, focusing on Chlamydomonas reinhardtii products.
  • The company signed a strategic agreement for significant product sales from 2026 to 2028.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Touyun Biotech Announces Strategic Cooperation Amid Unusual Market Activity

Meet Your ETF AI Analyst

China Touyun Tech Group ( (HK:1332) ) has provided an announcement.

Touyun Biotech Group Limited announced an unusual increase in its share price and trading volume, with no known reasons for these movements. The company confirmed that its operations remain normal and disclosed a strategic cooperation agreement with a sales consortium to purchase Chlamydomonas reinhardtii products worth at least RMB1 billion from 2026 to 2028, indicating potential growth opportunities.

The most recent analyst rating on (HK:1332) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Touyun Tech Group stock, see the HK:1332 Stock Forecast page.

More about China Touyun Tech Group

Touyun Biotech Group Limited, incorporated in Bermuda, operates in the biotechnology industry. The company, along with its subsidiaries, focuses on producing and marketing Chlamydomonas reinhardtii and related products, with a strategic market focus on expanding its reach through collaborations.

Average Trading Volume: 1,589,265

Technical Sentiment Signal: Hold

Current Market Cap: HK$1.08B

See more data about 1332 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1